Bibliography
- MANNING G, WHYTE DB, MARTINEZ R, HUNTER T, SUDARSANAM S: The protein kinase complement of the human genome. Science (2002) 298:1912–1934.
- CHERRY M, WILLIAMS DH: Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. Curr. Med. Chem. (2004) 11:663–673.
- PARGELLIS C, REGAN J: Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr. Opin. Investig. Drugs (2003) 4(5):566–571.
- BRENNAN FM, FELDMAN M: Cytokines in autoimmunity. Curr. Opin. Immunol (1996) 8:872–877.
- BAUGH JA, BUCALA R: Mechanisms for modulating TNF-a in immune and inflammatory disease. Curr. Opin. Drug Discov. Dev. (2001) 4(5):635–650.
- PALLADINO Mk BAHJAT FR, THEODORAKIS EA, MOLDAWER LL: Anti-TNF-a therapies: the next generation. Nat. Rev. Drug Discov. (2003) 2:736–746.
- GALLAGHER TF, FIER -THOMPSON SM, GARIGIPATI RS et al.: 2,4,5-Triarylimidazole inhibitors of IL-1 biosynthesis. Bioorg-. Med. Chem. Lett. (1995) 5:1171–1174.
- ADAMS JL, BOEHM JC, KASSIS S et al.: Pyrimidinylimidazole inhibitors of CSBP/ p38 kinase demonstrating decreased inhibition of hepatic cytochrome p450 enzymes. Bioorg-. Med. Chem. Lett. (1998) 8:3111–3116.
- ADAMS JL, BADGER AM, KUMAR S,LEE JC: p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. In: Progress in Medicinal Chemistry. King FD, Oxford AW (Eds), Elsevier Science BV (2001):1–60.
- TREJO AT, ARZENO H, BROWNER M et al.: Design and synthesis of 4-azaindoles as inhibitors of p38 MAP Kinase. J. Med. Chem. (2003) 46(22):4702–4713.
- TAMAYO N, LIAO L, GOLDBERG M et al.: Design and synthesis of potent pyridazine inhibitors of p38 map kinase. Bioorg-. Med. Chem. Lett. (2005) 15(9):2409–2413.
- LIVERTON NJ, BUTCHER JW, CLAIBORNE CF et al.: Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. (1999) 42:2180–2190.
- LAUGHLIN SK, CLARK MP, DJUNG JF et al.: The development of new isoxazolone based inhibitors of tumor necrosis factor-a (TNF-a) production. Bioorg-. Med. Chem. Lett. (2005) 15:2399–2403.
- CLARK MP, LAUGHLIN SK, LAUFERSWEILER MJ et al.: Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-a production. J. Med. Chem. (2004) 47(11): 2724–2727.
- GOLEBIOWSKI A, TOWNES JA, LAUFERSWEILER MJ et al.: The development of monocyclic pyrazolone based cytokine synthesis inhibitors. Bioorg-. Med. Chem. Lett. (2005) 15:2285–2289.
- LAUFERSWEILER MJ, BRUGEL TA, CLARK MP et al.: The development of novel inhibitors of tumor necrosis factor-a (TNF-a) production based on substitutech5,5l-bicyclic pyrazolones. Bioorg. Med. Chem. Lett. (2004) 14:4267–4272.
- TOWNES JA, GOLEBIOWSKI A, CLARK MP et al.: The development of bicyclic pyrazole based cytokine synthesis inhibitors. Bioorg-. Med. Chem. Lett. (2005) 15:2285–2289.
- DE LASZLO SE, VISCO D, AGARWAL L, CHANG L, O'KEEFE SJ: Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg-. Med. Chem. Lett. (1998) 8:2689–2694.
- DE DIOS A, SHIH C, DE URALDE BL et al.: Design of potent and selective 2-aminobenzimidazole-based p38a MAP kinase inhibitors with excellent in vivo Efficacy. J. Med. Chem. (2005) 48(7):2270–2273.
- ADAMS JL, VEAL J, SHEWCHUK L: Kinases. In: Protein Crystallography in Drug Discovery. Babine RE, Abdel-Meguid SS (Eds), Wiley-VCH Verlag GmbH & Co., Weinhem, Germany (2004):47–81.